Dianthus Therapeutics, Inc.
corporate_fare Company Profile
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for DNTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for DNTH spans 8-K, 4, 144, 10-Q.
Recent high-impact activity:
- Dianthus Q3: $1.2B Cash Into 2030, 75% CIDP Response Rate, MMN Data in December
- Dianthus Posts $46.6M Q3 Loss, Touts 75% CIDP Response Rate and $1.2B Cash Into 2030
- CEO Marino Garcia Sells $17.95M in Dianthus Stock Near 52-Week High
- Officer Marino Garcia Files to Sell $13.6M in Dianthus Therapeutics Stock
- Dianthus Posts $1.2B Cash, 75% CIDP Response Rate, and Advances gMG Phase 3
Financial Snapshot
Short Interest & Short Volume
10.14 days to coverFINRA reported short interest of 9,276,833 shares in DNTH as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 73.2% of DNTH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for DNTH, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.
New $500M ATM Program Established · Replaces Prior Shelf Capacity
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →